Ambrodil

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ambrodil

What is Ambrodil? Defining the Medicinal Entity

Property Description
Active Ingredient Ambroxol hydrochloride (INN)
Forms Syrup, Oral solution, Tablet, Inhalation solution, Injection
Pharmacological Class Mucolytic agent, Secretolytic agent
General Purpose Facilitates the clearance of thick mucus (sputum)
Origin Synthetic substance (Benzylamine derivative)

What Type of Medicine is Ambrodil?

Ambrodil is a medicinal preparation primarily classified as a mucolytic agent and secretolytic agent, utilized for addressing conditions involving abnormal or thick bronchial secretions. The drug's sole active ingredient is Ambroxol hydrochloride (INN), which is used in respiratory therapy for its profile of efficacy and safety.

Ambroxol is identified as a synthetic substance, specifically a benzylamine derivative that originates structurally from the compound bromhexine. Chemically, Ambroxol is a metabolite of bromhexine. The brand Ambrodil is often marketed in forms specifically targeting pediatric patients, offering syrup or oral solution formulations to facilitate ease of administration for younger age groups. As a secretolytic agent, it promotes the secretion of thinner fluid while simultaneously reducing the viscosity of existing mucus, thereby supporting the physiological clearance mechanisms of the respiratory tract.


What are the Available Forms and General Purpose of Ambrodil?

The general purpose of Ambrodil is to facilitate the expulsion of viscous sputum and improve the function of the body’s natural mucociliary transport system. The preparation is available in several dosage forms to suit diverse patient requirements, including syrup, oral solution, tablet, inhalation solution, and a solution for injection. This versatility allows for multiple routes of administration, primarily oral, inhalation, or parenteral (intravenous injection), to optimize the therapeutic approach.

A common use scenario involves patients with chronic respiratory ailments who require support to manage thick mucus production. The medication achieves its goal by modifying the physical composition of secretions and promoting the synthesis of pulmonary surfactant. When used for this purpose, Ambroxol is recognized for being generally well-tolerated.

What side effects are possible with Ambrodil?

Possible Side Effects and Safety Information

The safety profile of Ambrodil (Ambroxol hydrochloride) is organized by regulatory authorities based on the frequency and system-organ class of documented adverse reactions. The most Common effects, reported in official labeling (incidence of ge 1/100), are typically gastrointestinal or sensory. These include Nausea, Diarrhea, Dysgeusia (changed taste), and Oral/Pharyngeal Hypoesthesia (numbness of the mouth or throat).

Reactions categorized as Uncommon (incidence of ge 1/1,000) involve symptoms such as Vomiting, Abdominal Pain, Dyspepsia, Dry Mouth, Dry Throat, and Fever.


Serious Adverse Reactions and Constraints

Official regulatory documents specifically highlight the potential for Rare (incidence of ge 1/10,000) or Not Known frequency, but clinically significant, adverse events. These include severe Hypersensitivity Reactions and Anaphylactic Shock, as well as Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety constraints are defined for specific patient populations. Caution is required when Ambrodil is used in individuals with Severe Renal or Hepatic Impairment, as the accumulation of metabolites may be expected. Furthermore, a safety restriction exists against the concomitant use of Ambroxol with certain Cough Suppressants (antitussives), due to the potential risk of accumulated bronchial secretions.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based strictly on the official regulatory documentation for the active ingredient, Ambroxol hydrochloride, regarding documented overdose profiles.

Ambroxol is classified as having low systemic toxicity. An overdose is primarily characterized by symptoms that are an extreme extension of known side effects.

Documented Overdose Manifestations

Official prescribing information notes that manifestations of an overdose may include acute gastrointestinal distress, such as nausea, vomiting, diarrhea, and abdominal pain, as well as heartburn and indigestion. Systemic effects can include short-term restlessness and, in cases of extreme overdosage, hypotension (low blood pressure).

Required Emergency Actions

In the event of a suspected overdose, it is officially mandated to seek emergency medical treatment or contact a doctor immediately. This action is necessary regardless of the dose taken or the presence of symptoms.

  • Antidote: No specific antidote for Ambroxol overdose is available.
  • Management: Treatment is mainly symptomatic and supportive. Acute measures, such as gastric lavage (stomach pump), are not generally indicated and are reserved for the ingestion of a very high dose, usually within the first two hours.

Additionally, if signs of a progressive skin rash occur at any time, users must stop treatment immediately and seek medical advice.

Therapeutic Uses of Ambrodil

Ambrodil (Ambroxol) is commonly used to support patients in situations involving certain distressing symptoms related to physical discomfort. It is applied across domains where additional symptomatic support is needed for conditions where functional stability becomes affected. Its therapeutic use is considered relevant for easing symptoms related to inflammatory or irritative states.

The medication helps address symptom clusters that may become intense or disruptive, relevant in conditions involving episodic or fluctuating manifestations, or conditions associated with acute or disruptive episodes. This process contributes to easing the overall symptom load.

“This action is relevant in contexts involving heightened systemic burden, supports patients during episodes of heightened discomfort.”

This action is relevant in contexts involving heightened systemic burden, such as conditions characterized by periods of heightened symptoms. This process supports general well-being during symptomatic phases and may assist with maintaining functional stability.

Quick Fact: May Assist with Symptom Management

Regulatory References

  1. European Medicines Agency (EMA) Assessment Report

Eligibility and Restrictions for Use

Ambrodil, which contains the active ingredient ambroxol, is primarily indicated for patients with acute and chronic respiratory conditions that involve abnormal and excessive mucus secretion, such as bronchitis and chronic obstructive pulmonary disease (COPD).


Who Can Typically Use Ambrodil (Ambroxol)?

  • Adults and Older Children: The medication is generally prescribed for adults and children over the age of two or six years, depending on the specific formulation (e.g., syrup, tablet) and local guidelines.
  • Patients with Mucus-Related Respiratory Issues: Those experiencing difficulty clearing thick, tenacious mucus from the airways.

Who Should NOT Use Ambrodil (Contraindications)?

  • Known Allergy: Individuals with a documented hypersensitivity or allergy to ambroxol or the related drug bromhexine.
  • Severe Skin Reactions: Those with a history of rare but severe skin conditions such as Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
  • Pregnant and Breastfeeding Women: Use is generally not recommended during the first trimester of pregnancy, and caution is advised throughout gestation and while breastfeeding due to limited safety data.
Caution Advised (Consult Doctor) Reason for Caution
Gastric or Duodenal Ulcers Ambroxol may exacerbate existing peptic ulcer symptoms.
Severe Hepatic (Liver) Impairment The liver is involved in metabolizing the drug, and severe impairment may require dose adjustment.
Severe Renal (Kidney) Impairment Impaired kidney function can lead to accumulation of the drug and increased risk of side effects.

Patients should always discuss their full medical history and all current medications with a healthcare professional before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ambrodil (Ambroxol hydrochloride) is strictly defined by regulatory documents, focusing on pharmacodynamic conflicts and local pharmacokinetic outcomes with co-administered substances.

Interaction Classifications

Category Official Interaction Statement
Pharmacodynamic Risk Co-administration with antitussive agents, such as Codeine, is not recommended due to the officially recognized risk of secretion accumulation and potential airway obstruction resulting from the impaired cough reflex.
Local Pharmacokinetic Enhancement Co-administration with specific antibiotics, including Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline, results in a documented increase in antibiotic concentrations within bronchopulmonary secretions and sputum.

Population-Specific Interaction Notes

Official labeling includes population-dependent constraints related to drug clearance. An accumulation of hepatic metabolites is an expected outcome in patients with severe renal impairment due to altered elimination. Caution is also advised during administration in patients with severe hepatic impairment.

Regulatory documents explicitly confirm that no clinically relevant unfavorable interactions have been observed when Ambroxol is co-administered with standard medications for chronic bronchitis, such as corticosteroids and bronchospasmolytics. No mandatory time-separation rules are universally documented for administration.

Mechanism of Action

Ambrodil, containing ambroxol, exerts pharmacodynamic effects primarily through secretagogue and mucokinetic actions in the respiratory tract epithelium. The molecule stimulates the synthesis and secretion of pulmonary surfactant by Type II pneumocytes in the alveoli. Surfactant, acting as an anti-adhesive factor, reduces the molecular forces mediating mucus adhesion to the bronchial wall.

Simultaneously, ambroxol facilitates an increase in serous glandular secretion by submucosal glands, contributing to an overall increase in the volume of the periciliary fluid layer. This volumetric increase in the serous phase of the airway surface liquid lowers the viscosity of the overlaying mucus gel, thereby enhancing the ciliary beat frequency and overall mucociliary transport rate. Further molecular targets include the inhibition of neuronal voltage-gated sodium (Nav) channels, demonstrating a local anesthetic-like effect, and, at higher concentrations, a chaperone activity toward the lysosomal enzyme glucocerebrosidase (GCase), increasing its enzymatic levels and activity.

Dosage and Administration Information

How to Use Ambrodil

The usage of Ambroxol hydrochloride, the active component of Ambrodil, is based on established protocols and depends on the specific dosage form and route of administration. The medicine is available for oral intake (tablets, syrup, or extended-release capsules), inhalation via nebulizer, and parenteral/intravenous injection.


Official Dosing Regimens and Frequency

The standard adult dosing schedule for immediate-release (IR) oral forms utilizes a phased approach. Treatment generally begins with an initial dose of 30 mg administered three times daily, which is then typically reduced to a lower maintenance dose of 30 mg twice daily after the initial two to three days. The maximum daily dose may reach 120 mg in divided doses. In contrast, the 75 mg extended-release (ER) capsule is taken only once daily.

Administration Requirements and Adjustments

Oral formulations are generally instructed to be taken after a meal (with food). For the ER capsule, the medication must be swallowed whole with sufficient fluid and is strictly not to be crushed or chewed, a requirement tied to maintaining its proper release mechanism. The solution for inhalation is designated only for use with a nebulizing device.

Standard guidelines outline dose adjustments for specific populations. Pediatric patients require dosing based on age-stratified protocols or body weight, often utilizing specific oral liquid volumes. For patients with impaired renal or hepatic function, guidance mandates caution and may require the use of lower doses or extended time intervals between administrations.

Recent Clinical Evidence

Ambrodil: Recent Clinical Evidence

Evidence for Use in Secretolytic Therapy

Research has focused extensively on Ambrodil's use in conditions associated with acute or disruptive episodes and chronic disorders where mucus production is involved. The body of evidence includes short-term trials and systematic reviews used in research exploring how symptoms change over time. Studies monitored changes in objective measures, such as the characteristics of sputum, and subjective outcomes related to physical discomfort, including difficulty with expectoration and cough intensity scores.

The data show patterns related to how these outcomes changed in the observed populations during the study periods. Findings from various trials and meta-analyses reflect the scope of the evidence regarding symptom patterns in patients with both acute conditions and those with longer-term issues. This body of research describes how patients reported their experiences with breathing and mucus clearance when Ambrodil was studied for this approved indication.

Long-Term Studies and Follow-up

While many trials for acute symptoms focus on short defined time intervals (e.g., 7 to 14 days), some multicenter trials studies explored the use of the medicine over longer periods, such as six months, in individuals with chronic respiratory conditions. These extended observational settings evaluating daily-life functioning was observed in exploring patterns associated with conditions presenting with cycles of stability and flare-ups.

It is important to understand that while these longer studies research describes the trajectory of symptom patterns over several months, long-term effects are not fully established beyond the observed trial periods. There is limited information for long-term outcomes regarding the durability of responses after the observation period concluded.

Evidence in Special Populations

Ambrodil was evaluated in research involving specialized patient groups, including children and neonates. For the secretolytic indication, which has been studied for thick bronchial secretions, regulatory authorities have noted that data for certain groups remain insufficient. This includes specific age ranges where regulatory bodies have noted gaps in the research for the secretolytic indication. The available data show that evidence quality differs across age ranges within the pediatric population.

Separately, specific trials studies explored the use of the medicine, in contexts related to Infant Respiratory Distress Syndrome (IRDS) in premature newborns. These trials monitored outcomes related to systemic or functional imbalance, such as the newborn's need for mechanical breathing assistance and other markers of physiological strain. Research in this specialized area describes patterns associated with the neonatal condition, although evidence quality varies across studies.

What is Still Uncertain About Ambrodil

Research on Ambrodil, while extensive in the secretolytic field, has inherent limitations. The results apply only to the populations studied, and findings describe group patterns, not personal outcomes. Data for certain groups remain insufficient for long-term outcomes, and comparative evidence is lacking against every existing treatment option.

Furthermore, Ambrodil was observed in clinical trials examining its potential use in completely different areas, specifically neurodegenerative conditions marked by functional limitations, such as Parkinson's Disease. This is ongoing research into new uses that are not approved or established. Early trials, as documented in regulatory databases, often involve high doses and small patient cohorts, meaning certainty remains low and the findings were mixed regarding changes in primary clinical symptoms, although some studies have reported shifts in biological markers. Research provides context but not individual predictions for these investigational uses.

Key Studies & References

  1. WHO Collaborating Centre for Drug Statistics Methodology (ATC Classification for Ambroxol)
  2. Phase 2 Trial of Ambroxol in GBA1-related Parkinson's Disease (ClinicalTrials.gov)

Frequently Asked Questions (FAQ)

Common questions about Ambrodil (FAQ)


Q: What are the signs that Ambrodil might be causing an allergic reaction?

Official safety data indicates that serious allergic or hypersensitivity reactions, though rare, are possible. Signs of a severe reaction may include sudden rash, itchy eyes, angioedema (swelling of the deeper skin layers), or breathing difficulties, as listed in the product information. In rare cases, severe skin reactions with blistering and mucosal lesions have been reported.


Q: Can Ambrodil make you feel sleepy or drowsy?

Regulatory information and post-marketing data suggest that Ambroxol may cause side effects like drowsiness or dizziness in some users. Because the possibility of these effects exists, caution should be exercised when engaging in activities like driving or operating machinery until the individual response to the medication is known.


Q: What are the typical storage instructions for Ambrodil syrup?

Official regulatory documents specify that the product should be stored at a temperature not exceeding 30 C. It is also important to protect the syrup from direct light and moisture to maintain its efficacy, and to keep it in its original container.


Q: What is the maximum number of days or weeks one should take Ambrodil continuously?

According to the official product information, Ambrodil is generally not intended to be taken for more than four to five days without advice from a medical professional. For use extending beyond this defined duration, consultation with a healthcare professional is generally recommended.


Q: Can older adults take Ambrodil without special precautions?

While the effects of Ambroxol are not strongly altered by age alone, official guidance advises caution and special supervision for patients with severe kidney or liver impairment. Because conditions like these are more common in older adults, individuals in this age group may require special supervision or dose adjustment.


Q: Is Ambrodil the same as other cough syrups, or is it for a specific type of cough?

Ambrodil is a mucolytic agent, meaning its purpose is to thin and clear mucus, rather than suppress the cough reflex. It is considered more effective in treating a productive cough, which is a wet cough associated with the formation of thick, sticky mucus in the airways.


Q: How quickly should I expect to feel a difference after taking Ambrodil?

Clinical information suggests that the active ingredient in Ambrodil generally begins to work fairly quickly after oral administration. Most people may expect to start feeling its effects, such as mucus thinning, within about 30 minutes of taking the medication.


Q: Can I take Ambrodil if I'm already taking medicine for high blood pressure?

Official documents state that no adverse clinical interactions have been reported between Ambroxol and standard medications for chronic conditions, including some used to manage blood pressure, such as diuretics. As with any medication, it is important for patients to ensure their healthcare provider is aware of all current treatments.


Q: What kinds of non-prescription products or supplements might interact with Ambrodil?

Regulatory information suggests that the metabolism of Ambroxol may be increased when combined with certain supplements, such as St. John's Wort. It is advised to inform a healthcare provider of all non-prescription products and herbal supplements being taken.


Q: Is Ambrodil safe for children, and what's the difference between the adult and pediatric versions?

Ambrodil is generally available in specific formulations suitable for children, with dosing based on age-stratified protocols. The difference generally relates to the concentration and strength, with pediatric forms often being liquid to allow for precise, smaller doses.


Q: What should I do if I accidentally miss a dose of Ambrodil?

Official instructions indicate that if a dose is missed, it should generally be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. Patients are advised against taking a double dose to compensate for a single missed dose.


Q: Does Ambrodil have any effect on asthma symptoms?

Ambrodil is indicated for treating chronic inflammatory respiratory conditions that involve abnormal mucus secretion, and this includes conditions such as asthmatic bronchitis and bronchial asthma. Its role is focused on improving mucus clearance.


Q: Can Ambrodil cause any changes in my heart rate?

While changes in heart rate are not listed as a common side effect, very rare and serious reactions like anaphylactic shock can affect the cardiovascular system. If a person experiences rapid changes in their pulse or blood pressure, this should be immediately reported to a healthcare professional.


Q: Is there a specific time of day that is best for taking Ambrodil?

Official prescribing information for oral forms generally suggests taking the medication after food. Taking the medication after a meal is suggested, as this may help to minimize potential gastrointestinal side effects such as nausea or stomach upset.


Q: Is Ambrodil known to affect sleep patterns?

Some safety data indicates that Ambroxol is not typically associated with causing sleepiness or sleep disturbances. However, individual reactions can vary, and any unexpected change in sleep patterns should be reported to a doctor.


Q: Does Ambrodil build up in the body over time?

The half-life of Ambroxol, the time it takes for half of the substance to be eliminated, is between 7 and 12 hours. Preclinical investigations have not indicated that the drug builds up or accumulates in the body over time with regular use.


Q: Is it safe for individuals with diabetes to use Ambrodil syrup?

Because some syrup formulations may contain ingredients like sucrose or sorbitol, which can impact blood sugar, individuals with diabetes are typically advised to verify the specific excipient list of their prescribed formulation with a healthcare professional.


Q: Why does Ambrodil come in different strengths, and what is the typical starting dose?

Ambrodil is available in different strengths to allow for flexibility in the treatment approach. This often enables the use of a higher dose initially for the first few days, followed by a lower strength designated as the long-term maintenance dose.


Q: How does Ambrodil help with conditions like bronchiectasis?

Ambrodil is officially indicated for use in treating respiratory conditions such as bronchiectasis. Its primary mechanism of action is focused on thinning and clearing the thick, tenacious mucus associated with these chronic disorders.


Q: How is Ambrodil eliminated from the body?

The drug is rapidly and completely absorbed after oral intake and then primarily processed by the liver. The resulting metabolites are chiefly eliminated via the kidneys. Patients with severe kidney dysfunction may experience a prolonged half-life of these metabolites.


Q: Can I take Ambrodil if I have a history of stomach ulcers?

Official information advises caution when Ambrodil is used in individuals who have a history of peptic ulceration, which includes gastric or duodenal ulcers. A healthcare provider should be informed of any history of stomach ulcers.


Q: Does Ambrodil contain any sugar, alcohol, or common allergens?

Ambrodil formulations may contain various inactive ingredients (excipients). Official labeling shows that some versions contain small amounts of ethanol (alcohol), sucrose, sorbitol, or lactose. Patients with known allergies or dietary restrictions should check the specific ingredient list for the formulation they are using.


Q: Is it safe to drive or operate machinery after taking Ambrodil?

While studies have not shown a strong effect on driving ability, the potential for side effects such as drowsiness or dizziness exists. Caution should be exercised when engaging in activities that require full mental alertness, such as driving or operating machinery, until the individual response to the medication is established.

How should Ambrodil be stored and disposed of?

The storage and disposal of Ambrodil (Ambroxol hydrochloride) must strictly follow the official instructions provided in the regulatory labeling.

Storage Requirements

Condition Official Regulatory Requirement
Temperature Store at a temperature not exceeding 30 C (Store below 30 C).
Protection Protect from light and moisture.
Container Keep the medicine in its original container and keep the container tightly closed.
Security Keep the medicine out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired product must be done in accordance with local regulations. Medicines should not be disposed of in wastewater or general household trash. The preferred method is to utilize drug take-back programs or collection points available in your area. If no take-back program is available, the product may be mixed with an unappealing substance (like coffee grounds) and sealed before discarding in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ambrodil found in:

A-Z Index: